Adult Immunization Schedule

Recommendations for Ages 19 Years or Older, United States, 2024

< < Back to Adult Immunization Schedule by Age Group

¶ = Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity
§ = Recommended vaccination for adults with an additional risk factor or another indication
± = Recommended vaccination based on shared clinical decision-making
⇒ = No recommendation/Not applicable

adult vaccine schedule
Vaccine 19-26 years 27-49 years 50-64 years ≥65 years
COVID-19 more info icon. 1 or more doses of updated (2023-2024 Formula) vaccine (See notes
Influenza inactivated (IIV4) or
Influenza recombinant (RIV4) more info icon.
1 dose annually¶
more info icon.
Influenza live attenuated
(LAIV4) more info icon.
more info icon.
1 dose annually¶
Respiratory Syncytial Virus
(RSV) more info icon.
Seasonal administration during pregnancy. (See notes ± ≥60 years±
Tetanus, diphtheria, pertussis
(Tdap or Td) more info icon.
1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See notes
1 dose Tdap, then Td or Tdap booster every 10 years¶
Measles, mumps, rubella
(MMR) more info icon.
1 or 2 doses depending on indication
(if born in 1957 or later)¶
For healthcare personnel,
(See notes)
Varicella
(VAR) more info icon.
2 doses
(if born in 1980 or later)¶
§ 2 doses§
Zoster recombinant
(RZV) more info icon.
2 doses for immunocompromising conditions (See notes 2 doses¶
Human papillomavirus
(HPV) more info icon.
2 or 3 doses depending on age at initial vaccination or condition¶ 27 through 45 years± ±
Pneumococcal
(PCV15, PCV20, PPSV23) more info icon.
§ See Notes
See Notes±
Hepatitis A
(HepA) more info icon.
2, 3, or 4 doses depending on vaccine§
Hepatitis B
(HepB) more info icon.
2, 3, or 4 doses depending on vaccine or¶ condition§
Meningococcal A, C, W, Y
(MenACWY) more info icon.
1 or 2 doses depending on indication, See notes for booster recommendations§
Meningococcal B
(MenB) more info icon.
2 or 3 doses depending on vaccine and indication, See notes for booster recommendations§
19 through 23 years± §
Haemophilus influenzae type b
(Hib) more info icon.
1 or 3 doses depending on indication§
Mpox more info icon. §

Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Notes

For vaccine recommendations for persons 18 years of age or younger, see the Recommended Child and Adolescent Immunization Schedule.

Additional information

  • For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
  • Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
  • Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-2, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization.
  • Information on travel vaccination requirements and recommendations is available at cdc.gov/travel/.
  • For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization.
  • For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
  • The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the adult immunization schedule except PPSV23, RSV, RZV, Mpox, and COVID-19 vaccines are covered by the National Vaccine Injury Compensation Program (VICP). Mpox and COVID-19 vaccines are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

COVID-19 vaccination

Haemophilus influenzae type b vaccination

Hepatitis A vaccination

Hepatitis B vaccination

Human papillomavirus vaccination

Influenza vaccination

Measles, mumps, and rubella vaccination

Meningococcal vaccination

Mpox vaccination

Pneumococcal vaccination

Poliovirus vaccination

Respiratory syncytial virus vaccination

Tetanus, diphtheria, and pertussis (Tdap) vaccination

Varicella vaccination

Zoster vaccination

Addendum – Adult Recommended Immunization Schedule for ages 19 years or older, United States, 2024

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 26, 2023. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in Morbidity and Mortality Weekly Report (MMWR).

Vaccines

Vaccines

Vaccines

Recommendations

Recommendations

Recommendations

Effective Date of
Recommendation*

Effective Date of Recommendation*

Effective Date of
Recommendation*

No new vaccines or vaccine recommendations to report

Vaccines

No new vaccines or vaccine recommendations to report

Recommendations
Effective Date of Recommendation*

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.


Vaccines in the Adult Immunization Schedule*

adult vaccine schedule
Vaccine Abbreviation(s) Trade name(s)
COVID-19 vaccine 1vCOV-mRNA Comirnaty®/Pfizer- BioNTech COVID-19 Vaccine
Spikevax®/Moderna COVID-19 Vaccine
1vCOV-aPS Novavax COVID-19 Vaccine
Haemophilus influenzae type b vaccine Hib ActHIB®
Hiberix®
PedvaxHIB®
Hepatitis A vaccine HepA Havrix®
Vaqta®
Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix®
Hepatitis B vaccine HepB Engerix-B®
Heplisav-B®
PreHevbrio®
Recombivax HB®
Human papillomavirus vaccine HPV Gardasil 9®
Influenza vaccine (inactivated) IIV4 Many brands
Influenza vaccine (live, attenuated) LAIV4 FluMist® Quadrivalent
Influenza vaccine (recombinant) RIV4 Flublok® Quadrivalent
Measles, mumps, and rubella vaccine MMR M-M-R II®
Priorix®
Meningococcal serogroups A, C, W, Y vaccine MenACWY-CRM Menveo®
MenACWY-TT MenQuadfi®
Meningococcal serogroup B vaccine MenB-4C Bexsero®
MenB-FHbp Trumenba®
Meningococcal serogroup A, B, C, W, Y vaccine MenACWY-TT/MenB-FHbp Penbraya
Mpox vaccine Mpox Jynneos®
Pneumococcal conjugate vaccine PCV15 Vaxneuvance
PCV20 Prevnar 20
Pneumococcal polysaccharide vaccine PPSV23 Pneumovax 23®
Poliovirus vaccine IPV Ipol®
Respiratory syncytial virus vaccine RSV Arexvy®
Abrysvo
Tetanus and diphtheria toxoids Td Tenivac®
Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine Tdap Adacel®
Boostrix®
Varicella vaccine VAR Varivax®
Zoster vaccine, recombinant RZV Shingrix

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.


This schedule is recommended by the Advisory Committee on Immunization Practices  (ACIP) and approved by the Centers for Disease
Control and Prevention (CDC), American College of Physicians (ACP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), American Pharmacists Association (APhA), and Society for Healthcare Epidemiology of America (SHEA).

The comprehensive summary of the ACIP recommended changes made to the adult immunization schedule can be found in the January 11, 2024 MMWR.